This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

At what was supposed to be a hearing to discuss PBM reform, some in Congress veered off into discussions about Medicaid and ...

But major cuts to federal for Medicaid are a likely outcome of the $1.5-$2 trillion in spending cuts over the next 10 years ...

Unlike some other spending cuts, Medicaid cuts will have direct impact on people who voted for Republicans in November 2024, ...

Although the importance of ongoing education is known for patients, less than half of those with diabetes receive formal ...

The new lower prices apply to some doses of Zepbound provided in vials but not the autoinjector pens.

An expert discusses the significance of low-sodium oxybate for patients with narcolepsy patients with and cardiovascular disease and compares the diagnostic criteria and clinical presentations of ...

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa ...

There are four biosimilars of Stelara available to treat chronic autoimmune diseases — Wezlana, Selarsdi and now Pychiva and Yesintek. Sandoz and Biocon Biologics have each launched their biosimilar ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...